申请人:Foresee Pharmaceuticals Co., Ltd.
公开号:US10851089B2
公开(公告)日:2020-12-01
Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
描述了可作为基质金属蛋白酶(MMPs),特别是巨噬细胞弹性蛋白酶(MMP-12)抑制剂的海因基化合物。还描述了使用这些化合物抑制 MMP-12 和治疗由 MMP-12 介导的疾病(如哮喘、慢性阻塞性肺病 (COPD)、肺气肿、急性肺损伤、特发性肺纤维化 (IPF))的相关组合物和方法、肉样瘤病、系统性硬化症、肝纤维化、非酒精性脂肪性肝炎 (NASH)、关节炎、癌症、心脏病、炎症性肠病 (IBD)、急性肾损伤 (AKI)、慢性肾病 (CKD)、Alport 综合征和肾炎。